Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers (Q36363221)

13 August 2017

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers (English)

1 reference

13 August 2017

1 reference

1 reference

Vinata B Lokeshwar

1

1 reference

13 August 2017

Tomonori Habuchi

2

1 reference

13 August 2017

H Barton Grossman

3

1 reference

13 August 2017

William M Murphy

4

1 reference

13 August 2017

Stefan H Hautmann

5

1 reference

13 August 2017

George P Hemstreet

6

1 reference

13 August 2017

Aldo V Bono

7

1 reference

13 August 2017

Robert H Getzenberg

8

1 reference

13 August 2017

Peter Goebell

9

1 reference

13 August 2017

Bernd J Schmitz-Dräger

10

1 reference

13 August 2017

Jack A Schalken

11

1 reference

13 August 2017

Yves Fradet

12

1 reference

13 August 2017

Michael Marberger

13

1 reference

13 August 2017

Edward Messing

14

1 reference

13 August 2017

Michael J Droller

15

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

13 August 2017

1 reference

13 August 2017

66

1 reference

13 August 2017

6 Suppl 1

1 reference

13 August 2017

35-63

1 reference

Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Follow-up in non-muscle invasive bladder cancer: facts and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

A user's guide to flexible cystoscopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

The natural history of bladder cancer. Implications for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Hematuria home screening: repeat testing results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Three-year follow-up of bladder tumours found on screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

A community study of bladder cancer screening by the detection of occult urinary bleeding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Dipstick haematuria and bladder cancer in men over 60: results of a community study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Predisposition to urinary tract epithelial metaplasia in Schistosoma haematobium infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Aromatic amines and human urinary bladder cancer: exposure sources and epidemiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Case-control study of bladder cancer and drinking water arsenic in the western United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Filling the void: urinary markers for bladder cancer risk and diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

The accuracy of urinary cytology in daily practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Bladder cancer: state-of-the-art care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

A side by side comparison of cytology and biomarkers for bladder cancer detection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

A study comparing various noninvasive methods of detecting bladder cancer in urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Dangers of using "optimal" cutpoints in the evaluation of prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

What do we mean by validating a prognostic model?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Statistical aspects of prognostic factor studies in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Development tracks for cancer prevention markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Phases of biomarker development for early detection of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Prognostic factors: guidelines for investigation design and state of the art analytical methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Tumor markers in the diagnosis of primary bladder cancer. A systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urine based markers of urological malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Monitoring patients for bladder neoplasms: what can be expected of urinary cytology consultations in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Clinical significance of negative and equivocal urinary bladder cytology alone and in combination with DNA image analysis and cystoscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urinary tract cancer screening through analysis of urinary red blood cell volume distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Isolated asymptomatic microhematuria: a cross-sectional analysis of test-positive and test-negative patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Asymptomatic microscopic hematuria--is investigation necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparison of screening methods in the detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Value of urinary erythrocyte morphology in assessment of symptomless microhaematuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Evaluation of asymptomatic microscopic haematuria--influence and clinical relevance of osmolality and pH on urinary erythrocyte morphology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Usefulness of the BTA STAT Test for the diagnosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

The BTA stat test: a tumor marker for the detection of upper tract transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

HUMAN COMPLEMENT FACTOR H RELATED PROTEIN TEST FOR MONITORING BLADDER CANCER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Evaluation of the BTA tests for the detection of bilharzial related bladder cancer: the Cairo experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Qualitative determination of urinary human complement factor H-related protein (hcfHrp) in patients with bladder cancer, healthy controls, and patients with benign urologic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

The BTA stat test is nonspecific for hematuria: an experimental hematuria model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Utility of the BTA stat test kit for bladder cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Identification of a nuclear protein matrix.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

A fixed site of DNA replication in eucaryotic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

NuMA: an unusually long coiled-coil related protein in the mammalian nucleus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Detection of bladder cancer using a point-of-care proteomic assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Screening and monitoring for bladder cancer: refining the use of NMP22

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Functional characterization of the bladder cancer marker, BLCA-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Use of the novel marker BLCA-1 for the detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Survivin, versatile modulation of cell division and apoptosis in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urine detection of survivin and diagnosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Bladder cancer detection with urinary survivin, an inhibitor of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Expression of cytokeratin 20 redefines urothelial papillomas of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Qualitative and Quantitative Detection of Urinary Human Complement Factor H-Related Protein (BTA stat and BTA TRAK) and Fragments of Cytokeratins 8, 18 (UBC Rapid and UBC IRMA) as Markers for Transitional Cell Carcinoma of the Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and multiparametric DNA/cytokeratin flow cytometry in urine voided samples from patients with bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urinary cytokeratin 20 as a marker for transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Hyaluronan: a multifunctional, megaDalton, stealth molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Molecular detection of primary bladder cancer by microsatellite analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Detection of bladder cancer recurrence by microsatellite analysis of urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Accumulated allelic losses in the development of invasive urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Genetic alterations in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Microsatellite alterations in plasma DNA of small cell lung cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Microsatellite-based cancer detection using capillary array electrophoresis and energy-transfer fluorescent primers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Detecting bladder cancer in the Chinese by microsatellite analysis: ethnic and etiologic considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Life and cancer without telomerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Role of uCyt+ in the detection and surveillance of urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Analysis of genetic alterations in normal bladder urothelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Chromosomal aberrations in benign and malignant bilharzia-associated bladder lesions analyzed by comparative genomic hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Can biological markers replace cystoscopy? An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Do we have a prostate specific antigen for bladder cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

Home Screening for Hematuria: Results of a Multi-Clinic Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

inferred from DOI database lookup

7 January 2021

based on heuristic

Utilization of nuclear matrix proteins for cancer diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

inferred from DOI database lookup

7 January 2021

based on heuristic

Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.08.064

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2005.08.064

1 reference

13 August 2017

1 reference